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Vaccinerived vaccine, which is currently used in Indonesia to control the spread of
Jembrana disease in Bali cattle, was determined by quantifying the viral load in plasma following
experimental infection with Jembrana disease virus. Virus transmission is most likely to occur during the
acute phase of infection when viral titers are greater than 106 genomes/ml. Vaccinated cattle were found to
have a 96% reduction in viral load above this threshold compared to control cattle. This would reduce the
chance of virus transmission as the number of days above the threshold in the vaccinated cattle was reduced
by 33%. Viral loads at the onset and resolution of fever were signiﬁcantly lower in the vaccinated cattle and
immune function was maintained with the development of antibody responses to Env proteins within 10–
24 days post challenge. There was, however, no signiﬁcant reduction in the duration of the febrile period in
vaccinated animals. The duration and severity of clinical parameters were found to be variable within each
group of cattle but the quantiﬁcation of viral load revealed the beneﬁts of vaccinating to reduce the risk of
virus transmission as well as to ameliorate disease.
© 2009 Elsevier Inc. All rights reserved.IntroductionJembrana disease (JD) is an acute, sometimes fatal infection of the
immune system of Bali cattle in Indonesia, which ﬁrst occurred in Bali
in 1964. The causative agent, Jembrana disease virus (JDV), is a bovine
lentivirus (Kertayadnya et al., 1993) which is now endemic in Bali and
has spread to Bali cattle on the islands of Sumatra, East Java and
Kalimantan (Hartaningsih et al., 1993; Wilcox, 1997). Experimental
infection with JDV typically results in the development of a febrile
response and leukopenia within 5–12 days of challenge accompanied
by high viral titers of 108 ID50/ml equating to between 1010 and 1011
RNA genome copies/ml plasma (Soeharsono et al., 1995; Stewart et al.,
2005). The viremia peaks between 8–12 days post-challenge and then
declines as the febrile response and leukopenia resolve. Recovered
cattle remain persistently infected for at least 25 months but do not
appear to suffer any disease progression (Soeharsono et al., 1990).
Recovered animals develop a delayed humoral response several weeks
after infection prompting the assumption that antibody is not a major
factor in natural resolution of the acute disease process (Hartaningsih
et al., 1994). Recovered cattle are resistant to reinfection and neutra-
lizing antibody responses have been detected after 4–6 months in
some cattle (Soeharsono et al., 1990). Transmission of JDV has beenport).
ll rights reserved.reported to be similar to equine infectious anaemia virus (EIAV) and
is likely to occur via hematophagous arthropods during the acute
stage of the disease when viral titers in blood are high (Issel and Foil,
1984; Soeharsono et al., 1995). There is also evidence of transmission
of JDV during the acute stage of JD to susceptible cattle in close
contact in the absence of hematophagous arthropods, probably by
virus in secretions infecting cattle by the conjunctival, intranasal or
oral routes, which has been experimentally reproduced (Soeharsono
et al., 1995). Bloodmeal residues of between 4–10 nl have been
reported on the mouthparts of tabanid ﬂies and EIAV at 106 ID/ml in
blood can be transmitted by a single ﬂy (Foil et al., 1987; Hawkins
et al., 1976).
A vaccine that can effect a reduction in the duration andmagnitude
of viremia would be expected to reduce the risk of transmission in an
outbreak of JD. The most successful vaccines against animal lenti-
viruses are those which are based on whole or inactivated virus
preparations. Some degree of protection has been induced with
inactivated viral preparations in cats against feline immunodeﬁciency
virus (Hosie et al., 2000; Yamamoto et al., 1993), in horses against
EIAV (Issel et al., 1992) and against intravaginal challenge with
SHIV89.6 in macaques mucosally immunised with inactivated SHIV89.6
(Ambrose et al., 2003). However, potentiation of lentiviral disease
following vaccination is occasionally seen in goats vaccinated against
caprine arthritis encephalitis virus (Russo et al., 1993).
To control JD in Indonesia, an inactivated tissue derived viral
vaccine, JDVacc, has been developed that contains detergent inacti-
Fig. 1. ELISA absorbances indicating the development of IgG responses detected using
immobilized recombinant JDV p16 (A), recombinant JDV p26 (B), and circularized JDV
Tm peptide (C) after vaccination with JDVacc (days -67 and -39) and infection with
1000 ID50 JDVTAB/87 (day 0). Sequential serum samples were obtained from vaccinated
cattle CB75 (■), CB76 (▴), CB77 (▾), CB78 (♦) and control cattle CB83 (□), CB84 (Δ),
CB85 (▿) and CB86 (⋄).
Fig. 2.Western immunoblot indicating the development of IgG responses detected using
immobilized JDV ΔSU-GST after vaccination with JDVacc (days -67 and -39) and infection
with 1000 ID50 JDVTAB/87 (day 0). Sequential serum samples were obtained from
vaccinated cattle CB76 on days -67 (lane 1), -53 (lane 2), -39 (lane 3), 0 (lane 4), 3 (lane
5), 10 (lane 6), 17 (lane 7), 24 (lane 8), 28 (lane 9) and CB77 on days -67 (lane 10), -53
(lane 11), -39 (lane 12), 0 (lane 13), 3 (lane 14), 10 (lane 15), 17 (lane 16), 24 (lane 17), 28
(lane 18). Positive (lane 19) and negative (lane 20) control sera were also included.
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at the peak of viremia (Hartaningsih et al., 2001). The efﬁcacy of this
vaccine has been determined by analysis of clinical signs, in particular
the development and duration of the febrile response that develops
after experimental challenge with JDV (Hartaningsih et al., 2001).
Two doses of JDVacc (given 1 month apart) is the currently recom-
mended vaccination regime for Bali cattle in areas where JD
outbreaks are still occurring in Indonesia. Whilst the development
of a febrile response is a classical indicator of JD, we have recently
found that 15% of animals experimentally challenged with JDV did not
develop a febrile response, despite high levels of viral replication insome cases (Desport et al., 2009). The development of a qRT-PCR
assay in our laboratory for the detection of JDV RNA in plasma
(Stewart et al., 2005) has enabled the quantiﬁcation of the plasma
viral loads during the acute stage of infection. In this study, we sought
to determine the efﬁcacy of the 2 dose vaccination regime in pro-
tecting cattle in a JD outbreak situation by analysing viral loads (VL)
and immune responses after vaccination and challenge. A plasma
VL of 106 JDV genome copies/ml, approximately equivalent to
104 ID50/ml (Stewart et al., 2005) or b1 ID50 of EIAV per tabanid ﬂy
(Hawkins et al., 1976), was chosen as a threshold above which the risk
of transmission of virus is increased. A piecewise linear regression
model (Brandin et al., 2006) was ﬁtted to the data and used to esti-
mate missing data at the end of the plasma viraemia so that area
under the curve (AUC)≥106 genome copies/ml could be calculated
and compared in vaccinated and control cattle.
Results
Development of IgG responses after vaccination and challenge
Bali cattle were vaccinated twice with JDVacc and IgG antibody
responses against ﬁve JDV recombinant proteins determined using a
combination of ELISA and Western blot. Responses to the JDV matrix
protein (p16) were detectable in only one of the vaccinates prior to
challenge but all of the vaccinates seroconverted to this antigen 10–
24 days post-infection (Fig. 1A). All vaccinated cattle were found to
have seroconverted to the recombinant JDV p26 after the ﬁrst vacci-
nation with increasing ELISA absorbance values after the second
vaccination that were maintained after experimental infection (Fig.
1B). Antibodies speciﬁc to JDV Tat were not detected in any of the
vaccinated or control cattle at any of the available sampling times
(data not shown). None of the vaccinated cattle had detectable
antibody response against JDV ΔSu (Fig. 2) or JDV Tm peptide (Fig.
1C) prior to challenge but all cattle seroconverted to both antigens
between 10 and 24 days post challenge indicating an anamnestic
immune response. In contrast, the control group showed the char-
acteristic delay in seroconversion to JDV antigens with responses
detectable against JDV p16, p26 and Tm peptide beginning at 56 days
post-infection (Fig. 1). CB84 appeared to seroconvert strongly to the
JDV Tm peptide (Fig. 1C) but only weakly to JDV p26 compared to the
other control animals which had increasing ELISA absorbances from
day 60 (Fig. 1B). None of the control animals developed antibodies
that recognized the JDV p16 (Fig. 1A) or JDV ΔSu antigens (data not
shown).
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The efﬁcacy of this vaccine has been previously determined by
using its effect on the duration and magnitude of the febrile res-
ponse and the severity of the leukopenia as correlates of protection
(Hartaningsih et al., 2001). Three of the 4 animals in the control group
developed typical febrile responses (a rectal temperature of≥39.3 °C)
within 7–9 days of infection (Fig. 3). The fourth control animal, CB84,
developed a transient mild fever on day 12 post-infection. In the
vaccinated group, 2 of the 4 cattle developed febrile responses after a
similar period whilst CB76 developed fever 17 days post-infection and
CB78 did not develop elevated temperatures at any stage (Fig. 4). The
duration in days for the low, moderate and total febrile periods is
shown in Table 1. Therewere no signiﬁcant differences in the observed
data collected for the clinical responses that developed following
challenge with JDVTAB/87 between the vaccinated and the control
cattle. However, if the atypical responders (CB78 and CB84) were
excluded from the statistical analysis, the duration of the febrile res-
ponse in the vaccinated cattle was reduced (P=0.067) with the
period of moderate fever being signiﬁcantly shorter (P=0.051) in the
vaccinated cattle (Table 1).
Viral loads after vaccination and challenge with JDV
Although 2 of the 8 cattle failed to develop typical febrile res-
ponses, all animals had detectable levels of circulating plasma viral
RNA over the course of the experiment (Figs. 3 and 4). The atypical
control animal, CB84, exhibited an undulating low level plasma VL,
peaking at log10=7.93 genomes/ml (Fig. 3 and Table 2). The
vaccinated animal that did not develop a febrile response (CB78)
was found to have a plasma VL similar to the other vaccinates with aFig. 3.Dynamics of JDVTAB/87 replication in control GST vaccinated animals (CB83–86) after in
24 days post-infection. Plasma VL (JDV genome copies/ml plasma) was determined using
threshold of 106 genome copies/ml plasma (solid line) and AUC was determined frommeasu
(--), where measured data was unavailable.peak of log10=10.17 genomes/ml (Fig. 4 and Table 2). The VL on the
second day of the febrile response and on the ﬁrst day after the febrile
responsewere signiﬁcantly lower in the vaccinated animals compared
to the controls (Table 2). Peak plasma VL occurred earlier in the febrile
period and declined more rapidly than in the control group, whereas
higher levels of plasma virus persisted in the febrile controls for
several days and in CB83 and CB86, did not peak until 6 days after
onset of fever (Fig. 3). Signiﬁcant differences (P=0.017) in peak VL
were only observed when the atypical responders were not included
in the analysis (Table 2).
Comparison of observed and ﬁtted data
The ﬁtted piecewise linear regression was used to supply missing
points in the VL as they were not sampled for long enough to
determinewhen their VL dropped to b106 genomes/ml. The ﬁtted and
observed data points for both vaccinated and control cattle are shown
in Figs. 3 and 4. There were no signiﬁcant differences in the mean
model parameters estimated for the two groups. Themean duration of
the plateau phase (R–M), corresponding to the period in the disease
where viral replicationwasmatched by viral clearance, was reduced in
vaccinated animals (this approached signiﬁcance P=0.077). The Chi-
squared goodness-of-ﬁt test indicated there was no difference
between the observed data and the piecewise linear regression
model for all animals (P=0.66–0.99 for controls, and P=0.32–0.99
for vaccinates). The lower P values seen in 2 animals in the vaccinated
group were due to the ﬁtted line deviating from the measured results
in the pre-febrile period of viral replication. The proportion of the
sums-of-squares from these points was 73% and 86% of the total,
respectively. This deviation from the ﬁtted line was due to a reduction
in virus replication rates between 4–8 days post-challenge in thefectionwith 1000 ID50/ml JDVTAB/87 (day 0). Rectal temperatures (□) were collected for
qRT-PCR (●) and transformed to log10 scale. Differences in VL were calculated using a
red plasma VL (●) and ﬁtted VL, calculated using the piecewise linear regression model
Fig. 4. Dynamics of JDVTAB/87 replication in individual JDVacc vaccinated animals (CB75–78) after infection with 1000 ID50/ml JDVTAB/87 (day 0). Rectal temperatures (□) were
collected for 24 days post-infection. Plasma VL (JDV genome copies/ml plasma) was determined using qRT-PCR (●) and transformed to log10 scale. Differences in VL were calculated
using a threshold of 106 genome copies/ml plasma (solid line) and AUCwas determined frommeasured plasma VL (●) and ﬁtted VL, calculated using the piecewise linear regression
model (- -), where measured data was unavailable.
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observed to the same extent in the control animals.
Viral load in plasma of vaccinates and controls
The estimated mean total AUC was 5.4544×1011 for control cattle
and 2.2780×1010 genomes/ml for the vaccinated animals. TheTable 1
Comparison of observed data (days post infection) for the onset, peak and end of the
febrile response and peak viral load together with duration (days) of low (39.3–40.2 °C),
moderate (40.3–41.2 °C), high (N41.2 °C) and total febrile periods following challenge
with 1000 ID50 JDVTAB/87 in vaccinated (CB75–78) and control (CB83–86) Bali cattle
Cattle
no.
Peak
VL
Number of days post
infection
Duration of febrile response
(days)
≥39.3 °C Peak °C b39.3 °C Low Moderate Total
CB 75 10 8 11 14 2 4 6
CB 76 21 17 21 23 3 3 6
CB 77 11 9 12 14 2 3 5
CB 78 11 N/Aa 11 (39.1 °C) N/A 0 0 0
Mean 13.25 11.33 13.75 17 1.75 2.5 4.25
Var 26.92 24.33 23.58 27 1.58 3 8.25
CB 83 12 7 11 14 3 4 7
CB 84 13 12 12 13 1 0 1
CB 85 11 9 11 15 2 4 6
CB 86 12 7 12 15 3 5 8
Mean 12 8.75 11.5 14.25 2.33 3.25 5.5
Var 0.66 5.58 0.33 0.92 1.33 4.92 9.67
P-value 0.331 0.235 0.212 0.228 0.277 0.307
(0.051)b
0.288
(0.067)b
a N/A=not applicable.
b P-value calculated excluding atypical responders CB78 and CB84.estimated mean AUC≥106 genomes/ml was 5.4541×1011 and
2.2772×1010 equating to 99.995% and 99.961% of the total VL for
control and vaccinated animals respectively. In vaccinated cattle the
AUC≥106 genomes/ml was reduced by 96% compared to the control
cattle with a lower 95% conﬁdence limit (LCL) of 80%. When these
values were transformed to the log10 scale for statistical analysis
(Table 2), vaccinated typical responders were found to have a
signiﬁcantly lower AUC≥106 genomes/ml compared to normal
control cattle (P=0.018). There was a 33% reduction in the mean
duration of time that the plasma VL of vaccinated animals exceeded
106 genomes/ml which was signiﬁcantly different (P=0.031) from
the control cattle (Table 2).
Discussion
The protection provided after vaccination with a tissue-derived
inactivated virus vaccine that is currently used for the control of
Jembrana disease in Indonesia has not previously been determined.
JDVacc has been shown to reduce the duration and severity of JD and it
is likely that this amelioration of the acute phase of disease is
sufﬁcient to achieve a reduction in the mortality rates and reduce the
transmission of virus to other susceptible cattle (Hartaningsih et al.,
2001). The use of VL, a piecewise linear regression model and a
transmission threshold value has provided a method to determine
vaccine efﬁcacy in the context inwhich the vaccine is used. The beneﬁt
of a signiﬁcant reduction in VL in the vaccinated cattle during the early
febrile response and recovery period is revealed when expressed as a
33% reduction in the number of days when the plasma VL is above the
transmission threshold. Although this is an estimated threshold value
for the transmission of JDV, this encompasses N99.9% of the total VL in
Table 2
Comparison of plasma VL on the ﬁrst and second days of febrile response, ﬁrst day after the febrile response, peak VL, area under curve (AUC) for plasma VL≥106 genome copies/ml
and duration (days) of AUCN106 genome copies/ml following challenge with 1000 ID50 JDVTAB/87 in vaccinated (CB75–78) and control (CB83–86) Bali cattle
Cattle
no.
Log10 VL 1st
day≥39.3 °C
Log10 VL 2nd
day≥39.3 °C
Log10 VL 1st
dayb39.3 °C
Log10
peak VL
Log10 AUC≥106
genome copies/ml
Days AUC≥106
genome copies/ml
CB75 7.37 8.31 5.11 9.25 9.53 6
CB76 7.56 8.71 4.65 9.90 10.43 7.4
CB77 8.48 9.98 6.32 10.21 10.51 7.5
CB78 N/A a N/A N/A 10.17 10.50 6.2
Mean 7.80 9.00 5.36 9.88 10.23 6.8
Var 0.35 0.76 0.75 0.20 0.22 0.6
CB 83 10.08 10.97 9.82 11.76 12.22 12.2
CB 84 7.08 N/A 7.93 7.93 8.33 7.3
CB 85 10.06 10.36 6.53 10.63 11.02 9
CB 86 9.15 10.33 7.48 11.10 11.62 11.9
Mean 9.09 10.55 7.94 10.36 10.80 10.1
Var 1.99 0.13 1.91 2.83 2.95 5.6
P-value 0.086 (0.007)b 0.037 0.015 0.309 (0.017)b 0.282 (0.018)b 0.031
a N/A=not applicable.
b P-value calculated excluding atypical responders CB78 and CB84.
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efﬁcacy of JDVacc when used to control the spread of JDV in outbreak
situations.
The absence of detectable neutralizing antibodies after vaccination
with JDVacc in the original study (Hartaningsih et al., 2001), together
with poor antibody responses to Tm prior to challenge in this study
indicates that this vaccination regime does not engender the
development of strong humoral responses to Env antigens which
would be required to achieve sterilizing immunity. The use of JDVacc
has been demonstrated to induce antibody responses to several viral
proteins (Hartaningsih et al., 2001) but it was not possible to correlate
speciﬁc responses with protection from severe JD in such small groups
of cattle. Although antibodies are not believed to play an important
role in the clearance of JDV during natural infections, neutralizing
antibodies have been reported to develop 4–6 months post-infection
(Hartaningsih et al., 2001) and passive antibody treatment of
macaques prior to challenge with SHIV has induced sterilizing
immunity (Mascola et al., 1999).
The responses to the Gag proteins appeared to develop early after
vaccination but this reﬂects their relative abundance compared to Env
proteins in the vaccine preparation. The variation seen in the JDV ΔSU
responses of the vaccinated cattle compared to the controls could have
been due to the use of detergent in the preparation of JDVacc as this
would have denatured the native SU protein. Alternatively, the
production of a truncated recombinant SU antigen in an Escherichia
coli expression system may not represent the immunodominant
epitopes that are present on the native full length protein. Indeed, only
a clone representing the extracellular domain of BIV Env was able to
detect SU-speciﬁc antibodies after experimental infection with BIV
(Chen et al., 1994). The absence of a detectable response to JDV Tat was
not unexpected, as JDV Tat is only reported to be highly expressed
early in infection (Setiyaningsih et al., 2008) and is unlikely to be
present at high levels in JDVacc. The development of antibody
responses to both Su and Tm in all of the vaccinated cattle at
3 weeks post-infection suggested that a normal memory B cell
response developed following vaccination and challenge. The immu-
nosuppression that is characteristically observed with JD (Wareing
et al., 1999) did not appear to inhibit the development of virus speciﬁc
antibodies following infection. This would be an additional beneﬁt of
vaccination as infected cattle frequently succumb to secondary
infections as a result of the immunosuppressive effect of JDV (Dharma
et al., 1991). Circulating antibodies to JDV in the control animals were
not detectable until at least 8 weeks post-infection, conﬁrming earlier
studies (Hartaningsih et al., 1994). Unfortunately, analysis of the
cellular immune responses to vaccination and long-term analysis of
the persistence of the virus after vaccination were not possible with
the resources available in Bali.Vaccinated animals exhibited lower peak VLs compared to the
controls, indicating that a low level of virus neutralization or
reduction in early spread of virus may be due to the humoral immune
responses generated after vaccination. The role of neutralizing anti-
bodies in providing protection in other lentivirus challenge systems is
uncertain and controversial (Issel et al., 1992; Sattentau, 1996) and in
some cases antibody-dependent enhancement of virus replication or
absence of any correlation between protection and humoral para-
meters have been reported (Mazzetti et al., 1999; Raabe et al., 1999).
The most signiﬁcant effects of JDVacc appear after the peak VL when
the vaccinates cleared circulating virus much faster than the control
animals. The elevated rectal temperatures at lower viral titers in the
vaccinated group suggest that the effective viral clearancewas due to a
primed CMI response.
We have recently observed that 15% of cattle experimentally
infected with JDV, including CB84 in this study, fail to develop the
typical clinical signs associated with JD (Desport et al., 2009). These
cattle typically have much lower peak VL and AUC ≥106 genomes/ml
compared to normal responders. This suggests that there may be a
threshold of disease induction where a particular virus burden is
required to trigger the release of pro-inﬂammatory cytokines and
other factors which can cause pyrexia. This phenomenon has been
observed for EIAV and is proposed to be between 5×107 to 1×108 RNA
copies/ml for infection in horses (Cook et al., 2003). The consistent
reduction in VL and febrile responses in the vaccinates compared to
the typical controls and the lower peak VL in CB84 correlates well with
the virus threshold theory that reduction of viral titers can ameliorate
disease as well as reducing the risk of virus transmission. Cats with
rapidly progressive FIV infection have been shown to have viral RNA
loads 1–2 log10 higher than long term survivors and this difference in
VL is present early in infection (Diehl et al., 1996). It was not possible
to attribute the absence of a febrile response after vaccination and
challenge in CB78 to efﬁcacy of JDVacc, particularly as this animal had
a peak VL which was similar to the other vaccinates. Comparable
results have been seen in SIV-infected macaques in vaccine trials, with
varying patterns of virus replication apparently unrelated to the
vaccines being tested (Silvera et al., 2002; Waisman et al., 1996). A
decrease in the magnitude and duration of the febrile response has
been the most commonly employed correlate of protection for JDVacc
(Hartaningsih et al., 2001) but the trend for a febrile response to be
induced at lower levels of virus in the vaccinated animals in this study
highlights the balance between effective immune activation and
potentiation of viral replication. Immune activation has been shown to
facilitate viral replication in several different lentiviral infections
(Fauci et al., 1991; Poli and Fauci, 1993) and in some cases disease
potentiation has occurred post-vaccination (Issel et al., 1992;
Richardson et al., 2002).
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vaccinated animals did not develop a febrile response or leukopenia
after challenge (Hartaningsih et al., 2001). Differences between the
two challenge experiments could have arisen due to the method of
preparation of virus by passage through a donor animal or could be
related to the additional vaccination and lower challenge dose used in
the earlier study. The serological responses to viral antigens other than
JDV p26 were only apparent after the third vaccination in the previous
study indicating that a more mature immune response had developed
prior to virus challenge. Protection against homologous EIAV chal-
lenge in 14 out of 15 ponies was achieved after 5–8 vaccinations with
an inactivated whole virus vaccine although it was not sufﬁcient to
prevent infection when a heterologous EIAV strain was used as the
challenge virus (Issel et al., 1992). JDV strains in Bali appear to be
highly genetically conserved (3% amino acid heterogeneity in env)
and it is expected that JDVacc should offer good protection to cattle on
this island (Desport et al., 2007). However, a JDV strain detected in
Indonesian Borneo (Kalimantan) was divergent from strains detected
in Bali (13% amino acid heterogeneity in env compared to JDVTAB/87)
and it will be important to determine whether using JDVTAB/87 as the
vaccine strain will offer sufﬁcient protection against virus strains in
Kalimantan.
In conclusion, despite the problems inherent in attempting immu-
nological control of lentivirus infections and atypical responses to
challenge within small groups of animals, it was noted that vacci-
nation of Bali cattle with inactivated virus onlymarginally reduced the
duration of the acute clinical signs of infection yet signiﬁcantly
reduced the magnitude and duration of VL after challenge with JDV.
These factors would be expected to reduce the window of opportu-
nity for transmission of JDV via close contact or hematophagous
arthropods such as tabanid ﬂies to naïve cattle thus helping to contain
the spread of virus. By determining the duration andmagnitude of the
VL≥106 genomes/ml, we have developed a much improved method
for assessing the efﬁcacy of JDVacc after challenge, which is directly
relevant to its use in JD outbreak situations.
Materials and methods
Animals
Eight female Bali cattle between 6 and 12 months of age were
purchased and housed as previously described (Soeharsono et al.,
1990). Animals were housed for 1 week prior to vaccination and were
tested by ELISA (Hartaningsih et al., 1994) to ensure that they were
JDV seronegative.
Vaccination of cattle
The vaccine, JDVacc, was prepared as previously described
(Hartaningsih et al., 2001). Brieﬂy, the capsule was removed from
the spleen of an animal experimentally infected with the JDVTAB/87,
and was homogenised at a ratio of 10% w/v in Medium 199 at
4 °C. Virus was inactivated by the addition of Triton-X 100 to a
ﬁnal concentration of 1% v/v and subsequent stirring for 30 min at
room temperature. The antigen preparation was mixed and
homogenised with a mineral oil adjuvant (MOA) at a ratio of
2:1 MOA:antigen.
Two vaccinations, each of 1 ml, were administered intramuscularly
into the neck of four cattle at 67 and 39 days before infection with
JDVTAB/87. The four control animals were given 3×1 mg/ml doses of
glutathione-s-transferase (GST) homogenised in an equal volume of
incomplete Freund's adjuvant (IFA) at 67, 53 and 32 days before
experimental infection. Cattle were monitored daily for any signs of
clinical disease and the absence of any febrile response after
vaccination indicated that the vaccine preparation did not contain
infectious virus.Experimental infection with JDVTAB/87
All animals in this experiment were challenged intravenously with
an estimated 1000 ID50 of JDVTAB/87, quantiﬁed using capture ELISA
(Stewart et al., 2005). Clinical signs and rectal temperatures were
monitored daily up to 23 days post-infection. Blood samples were
collected into EDTA for plasma collection on days 0, 3, 5, 7 and any
days when the rectal temperature was ≥39.5 °C. Serum samples were
collected at 0, 4, 5, 10 and 13 weeks post-vaccination for all cattle and
samples from weeks 15, 17 and 26 were taken from the control GST
vaccinated group only.
Viral RNA quantiﬁcation
Viral RNA was prepared from 280 μl of plasma from each time-
point using a QIAmp Viral RNA mini kit (QIAGEN) following the
manufacturer's instructions, with a ﬁnal elution volume of 60 μl in
buffer EB. qRT-PCR was performed as previously described using
Access RT-PCR kit (Promega) (Stewart et al., 2005). Each sample was
assayed in duplicate using 2 μl RNA in a reaction volume of 25 μl with
ﬂuorescence excited at a wavelength of 470 nm and detected at a
wavelength of 510 nm. The one-step RT-PCR protocol consisted of an
RT step at 48 °C for 45 min, a 3 min inactivation step at 95 °C, followed
by 40 cycles of 95 °C for 30 s, 58 °C for 30 s and 60 °C for 30 s. The
ﬂuorogenic probe and primers were designed to amplify and detect a
121 bp fragment of the JDV gag gene as previously described (Stewart
et al., 2005). The limit of detection of the assay was 9.8×102 JDV
viral RNA copies over 35 cycles, equivalent to 4.2×104 JDV genome
copies/ml plasma.
Immunoblot and ELISA analysis of anti-JDV IgG responses
Serum samples were tested using a combination of ELISA and
Western immunoblot for the presence of antibodies to recombinant
JDV proteins using viral antigens expressed in E. coli strain JM109. All
recombinant viral proteins were derived from JDVTAB/87 sequences
(Chadwick et al.,1995) and cloned into the PinPoint expression system
(Promega) as previously described (Desport et al., 2005). The JDV
recombinant constructs included p16 (matrix protein encoded by
nucleotides 229–604), p26 (capsid protein encoded by nucleotides
604–1287), ΔSU (N-terminal truncated surface unit protein encoded
by nucleotides 5556–6463) and Tat1 (encoded by nucleotides 5010–
5303). Western immunoblots were prepared using 2000 ng of the
recombinant proteins and after overnight transfer, membranes were
blocked using 5% skimmed milk in PBST for 30 min at room tempe-
rature. Test sera were diluted 1:50 in blocking solution and incubated
for 1 h at room temperature. A 1:2000 dilution of rabbit anti-bovine
IgG-HRP (BioRad) in PBS/T was used, followed by detection using the
Bio-Rad HRP detection reagents. Serological responses were further
investigated by ELISA using Maxisorb plates (Nunc). Coating antigens
were either recombinant JDV p26 (12.5 ng/well) or JDV p16 (50 ng/
well) or a cyclic JDV Tm peptide KVQTGLGCVPRGRYGHFD (1 μg/well)
equivalent to the BIV peptide TMA2 which has previously been
identiﬁed as encompassing the principle immunodominant domain
(Scobie et al., 1999). All dilutions were prepared in 5% skimmed milk
powder in PBS/Tand plateswere incubated at each step for 1 h at 37 °C
and thenwashed 3 times with PBS/T. A 1:2000 dilution of rabbit anti-
bovine IgG-HRP in PBS/T (BioRad)was used as the secondary antibody
in each assay and the BioRad HRP substrate reagent was added to the
plates and allowed to develop for 15 min. The reaction was stopped
with2%oxalic acid and the absorbancewasmeasured at 405nm(A405).
Piecewise linear regression and statistical analysis
In order to supply missing data caused by variations in disease
onset or sampling intervals, a piecewise linear model was used which
323W.G.F. Ditcham et al. / Virology 386 (2009) 317–324was ﬁtted separately for the available data from each animal. The
model had 5 parameters; 3 inﬂection points (D, M and R), a growth
rate (a) and clearance rate (b). D, M and R were deﬁned by time in
days to initial appearance of virus in plasma (day D) observed after
infection, whenmaximumplasma VLwas achieved (dayM) andwhen
net viral loss began (day R). In the model, t is time in days post-
infection and v is virus per ml. The four stages are deﬁned in the
model as:Delay stage Ln(v)=0 for t≤D,
Growth stage Ln(v)=a(t−D) for Db tbM,
Plateau stage Ln(v)=a(M−D) for M≤ t≤R,
Clearance stage Ln(v)=a(M−D)−b(t−R) for Rb t.R–M represented the duration of the plateau period where viral
growth and loss were approximately equal. Because the “slopes” a and
b were determined on the log (Ln) viral and linear time scales they
represented growth and clearance rates respectively on the untrans-
formed viral scale. The model parameters were estimated by
minimizing the total residual sum of squares between the observed
and ﬁtted values and parameter estimates for the two groups were
compared with a two-tailed Students 2-sample t test. The sums-of-
squares for the differences between the measured data points and the
ﬁtted points were calculated, and the Chi distribution used to assess
the goodness of ﬁt of the piecewise regression.
Analysis of vaccine efﬁcacy
Vaccine efﬁcacy was determined by testing for differences in: (i)
VL on ﬁrst and second days of fever and on ﬁrst day after the end of
fever; (ii) duration of time and magnitude of VL where
AUC≥106 genomes/ml; (iii) duration of the febrile period. The total
VL (AUC) for each animal was estimated by summing the areas under
each pair of observations that form sets of trapezoids. The trapezoid-
area was determined as h⁎([v+w]/2), where h was the time in days
between consecutive viral determinations (denoted v and w) in
genomes/ml. Where critical observations were missing (i.e. the start
and ﬁnish of viral excretion) the piecewise model was used to
estimate the time of these events so that a total AUC could be
estimated for each animal. The duration of the infectious period was
deﬁned as the period where VL≥106 genomes/ml. This was
determined as described above but with a baseline set at 106 rather
than zero. Linear interpolation between consecutive observations was
used to more accurately determine the time when VL exceeded or fell
below 106 genomes/ml. In three of the control animals (CB83, 85 and
86) and one vaccinated animal (CB78) the sampling ﬁnished before
the viremia fell below 106 genomes/ml so the piecewise model was
used to generate this data. This required extrapolation beyond the last
data point for 1 day for three animals and for 2 days for CB83 (Figs. 3
and 4). For data analysis in this study, rectal temperatures were
divided into ranges adapted from the method of Muraguri (Muraguri,
Kiara, and McHardy, 1999) taking 39.3 °C as the lowest signiﬁcant
pyrexia. The ranges were deﬁned as low fever (39.3 °C–40.2 °C),
moderate fever (40.3 °C–41.2 °C) and high fever (N41.2 °C).
Statistical analysis
The mean and 95% conﬁdence limits for percentage viral load and
infectious period reductions were estimated using the method of
Coles et al. (1992). The VL on the ﬁrst and second days of elevated
rectal temperatures (≥39.3 °C), the ﬁrst day after the febrile period
had resolved and the peak and area under the curve≥106 genome
copies/ml values were log10 transformed to stabilise the variance
between groups. Student's t test was used for statistical compa-
rison of observed data and magnitude and duration of plasma VL.
P-valuesb0.05 were considered statistically signiﬁcant.Acknowledgments
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